Immunogenicity assessment of AAV-based gene therapies: An IQ consortium industry white paperTong‐Yuan Yang, Vibha Jawa, Stephen DeWall et al.|Molecular Therapy — Methods & Clinical Development|2022Cited by 113
Preexisting antibody assays for gene therapy: Considerations on patient selection cutoffs and companion diagnostic requirementsManuela Braun, Mark Milton, Wibke Lembke et al.|Molecular Therapy — Methods & Clinical Development|2024Cited by 25
PK/PD and Bioanalytical Considerations of AAV-Based Gene Therapies: an IQ Consortium Industry Position PaperUma Kavita, Nagendra Chemuturi, Vijay Upreti et al.|The AAPS Journal|2023Cited by 17
Immunogenicity Risk Assessment for Nucleic Acid Therapeutics: A Comprehensive Evaluation for ASO, siRNA, and Nonvaccine mRNA/LNP Therapies by the IQ ConsortiumJoanna Grudzinska‐Goebel, Vibha Jawa, Linzhi Chen et al.|Nucleic Acid Therapeutics|2025Cited by 6